Immunohistochemical expression of p53, bcl-2, and p21WAF1/CIP1 in early cervical carcinoma: Correlation with clinical outcome

2002 ◽  
Vol 12 (3) ◽  
pp. 290-298 ◽  
Author(s):  
M Graflund ◽  
B Sorbe ◽  
M Karlsson
Keyword(s):  
Survival Rate ◽  
Clinical Outcome ◽  
Cervical Carcinoma ◽  
Early Stage ◽  
Tumor Grade ◽  
Figo Stage ◽  
Immunohistochemical Expression ◽  
Cancer Specific Survival ◽  
Term Survival ◽  
Cervical Carcinomas

Abstract.Graflund M, Sorbe B, Karlsson M. Immunohistochemical expression of p53, bcl-2, and p21 WAF1/CIP1 in early cervical carcinoma: Correlation with clinical outcome.The objective of this study was to assess the value of p53, bcl-2, and p21WAF1/CIP1 immunoreactivity as predictors of pelvic lymph node metastases (LNM), recurrences, and death due to the disease in early stage (FIGO I-II) cervical carcinomas. FIGO stage, type of histopathology, and tumor grade were also evaluated in this series of patients treated by radical hysterectomy (Wertheim-Meigs) between 1965 and 1990. A total of 172 patients were included. A tumor was regarded as positive when more than 30% of the neoplastic cells exhibited immunoreactivity. Positive immunostaining was found in 8.9% for p53, in 43.5% for bcl-2, and in 25.0% for p21WAF1/CIP1. None of them was able to predict LNM or clinical outcome. Presence of LNM, tumor recurrence, and death from disease were significantly associated with the FIGO stage (P = 0.014, P = 0.009, and P = 0.001, respectively). The 5-year cancer-specific survival rate was 91.6% and the overall survival rate was 90.5%. It was concluded that immunohistochemically detected p53, bcl-2, and p21WAF1/CIP1 appeared to be of no predictive value with regard to LNM, tumor recurrences, or long-term survival in early cervical carcinomas.

The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy

2002 ◽  
Vol 12 (3) ◽  
pp. 265-276 ◽  
Author(s):  
I Skirnisdóttir ◽  
T Seidal ◽  
E Gerdin ◽  
B Sorbe
Keyword(s):  
Prognostic Factors ◽  
Survival Rate ◽  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Tumor Grade ◽  
Figo Stage ◽  
Epithelial Ovarian Carcinoma ◽  
Cancer Specific Survival ◽  
Persistent Disease ◽  
Prognostic Importance

Abstract.Skirnisdóttir I, Seidal T, Gerdin E, Sorbe B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.Epithelial ovarian cancer is one of the major causes of death among women. The increasing knowledge about molecular events involved in the early stages of ovarian tumorigenesis may provide the basis for management in the future. In a series of 109 patients with epithelial carcinomas in FIGO stages IA-IIC, a number of clinicopathologic prognostic factors (age, FIGO stage, histopathologic type, and tumor grade) were studied in relation to the biologic factors p53, bcl-2, and bax, which are important regulators of apoptosis. Immunohistochemical techniques were used. All the patients received adjuvant chemotherapy after the primary surgery. Univariate analysis showed that expression of p53 was significantly associated with tumor grade (P = 0.014), probability of persistent disease (P = 0.016), and cancer-specific survival rate (P = 0.007). Positive bcl-2 staining was associated with endometrioid tumor subtype (P = 0.029) and a favorable tumor grade distribution (P = 0.034), but not with the survival status. The combined p53-bcl-2 expression was related to histopathologic subtype (P = 0.032), tumor grade (P = 0.011), persistent disease (P = 0.014), and risk of dying due to the disease (P = 0.039). The bax status was not a prognostic factor, but the combined p53-bax expression showed an association with FIGO stage (P = 0.014), tumor grade (P = 0.034), persistent disease (P = 0.006), and risk of dying due to the disease (P = 0.039). The combined bcl-2-bax expression was related to histopathologic subtype (P = 0.045) and tumor grade (P = 0.022). In a multivariate Cox analysis, tumor grade (P = 0.014), and p53 status (P = 0.020) were independent and significant prognostic factors with regard to the cancer-specific survival rate.

scholarly journals Clinicopathological characteristics and prognostic factors of cervical adenocarcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Min Wang ◽  
Bo Yuan ◽  
Zhen-huan Zhou ◽  
Wei-wei Han
Keyword(s):  
Prognostic Factors ◽  
Tumor Size ◽  
Survival Rates ◽  
Tumor Grade ◽  
Figo Stage ◽  
Cervical Adenocarcinoma ◽  
Stage Ii ◽  
Prognostic Indicators ◽  
Rank Test ◽  
Cancer Specific Survival

AbstractWe aimed to assess the clinicopathological features and to determine the prognostic factors of cervical adenocarcinoma (AC). Relevant data were extracted from surveillance, epidemiology and end results database from 2004 to 2015. The log-rank test and Cox proportional hazard analysis were subsequently utilized to identify independent prognostic factors. A total of 3102 patients were identified. The enrolled patients were characterized by higher proportion of early FIGO stage (stage I: 65.9%; stage II: 14.1%), low pathological grade (grade I/II: 49.1%) and tumor size ≤ 4 cm (46.8%). The 5- and 10-year cancer-specific survival rates of these patients were 74.47% and 70.00%, respectively. Meanwhile, the 5- and 10-year overall survival (OS) rates were 71.52% and 65.17%, respectively. Multivariate analysis revealed that married status, surgery as well as chemotherapy were independent favorable prognostic indicators. Additionally, aged > 45, tumor grade III/IV, tumor size > 4 cm, advanced FIGO stage and pelvic lymph node metastasis (LNM) were unfavorable prognostic factors (all P < 0.01). Stratified analysis found that patients without surgery could significantly benefit from chemotherapy and radiotherapy. In addition, chemotherapy could significantly improve the survival in stage II–IV patients and radiotherapy could only improve the survival in stage III patients (all P < 0.01). Marital status, age, grade, tumor size, FIGO stage, surgery, pelvic LNM and chemotherapy were significantly associated with the prognosis of cervical AC.

Gender differences in outcomes for early-stage colon cancer.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 605-605 ◽  
Author(s):  
Sina Alipour ◽  
Hagen F. Kennecke ◽  
Howard John Lim ◽  
Winson Y. Cheung
Keyword(s):  
Gender Differences ◽  
Colon Cancer ◽  
Survival Rate ◽  
Cox Regression ◽  
Early Stage ◽  
Population Based ◽  
Stage Ii ◽  
Cancer Specific Survival ◽  
Interaction Terms ◽  
Early Stage Colon Cancer

605 Background: Retrospective analyses of clinical trials suggest that gender may influence the risk of recurrence and survival in patients diagnosed with early stage colon cancer. Whether this association persists in the setting of routine clinical practice is unclear. Our aims were to 1) assess for gender differences in outcomes in early stage colon cancer and 2) evaluate if the effect of gender on outcomes is modified by adjuvant therapy (AT). Methods: Using a population-based cohort of patients diagnosed with stage II or III colon cancer and referred to any 1 of 5 regional cancer centers in British Columbia, Canada from 2001 to 2005, we compared 5-year outcomes between men and women. Multivariate Cox proportional hazard models were constructed to explore the relationships between gender and prognosis, while controlling for patient and tumor characteristics. Interaction terms between gender and AT were used to examine the predictive value of gender. Results: We included 1837 patients: 970 men and 867 women. Baseline characteristics were similar: median ages were 68 and 69 years; 39 and 38% had stage II colon cancer; and 46 and 44% received AT, respectively. Outcomes were better in women than in men (5-year cancer-specific survival rate 73 vs. 71% and 5-year overall survival rate 68 vs. 62%). In Cox regression models, women continue to experience better overall prognosis (HR for death = 0.80, 95% CI 0.69-0.92, p=0.003) when compared to men. Advanced age, stage III disease, and lack of AT also correlated with worse outcomes (all p<0.01). The effect of gender on outcomes remained similar regardless of AT (HR 0.86 among women with AT and HR 0.75 among women without AT, interaction p=0.35). Conclusions: Gender is a prognostic, but not a predictive, factor for this cohort of patients with early stage colon cancer. Studies to investigate the biological mechanisms underlying this gender difference in outcomes are warranted.

Expression of differentiation associated protein Hes1 and Hes5 in cervical squamous carcinoma and its precursors

2007 ◽  
Vol 17 (6) ◽  
pp. 1293-1299 ◽  
Author(s):  
J. Liu ◽  
F. Ye ◽  
H. Chen ◽  
W. LÜ ◽  
C. Zhou ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Poor Prognosis ◽  
Early Stage ◽  
Squamous Carcinoma ◽  
Severe Dysplasia ◽  
Prognostic Variables ◽  
Cervical Carcinomas ◽  
Helix Loop Helix ◽  
Epithelial Lesions ◽  
Enhancer Of Split

Hairy and Enhancer-of-split homologues 1 and 5 (Hes1 and Hes5) are the basic helix-loop-helix transcriptional factors that negatively regulate the cell differentiation during embryogenesis. It has been reported that they may be involved in carcinogenesis in some tumors. The roles of Hes1 and Hes5 in development and progression of cervical carcinoma are not well documented todate. In the study, the expression of Hes1 and Hes5 were detected by immunohistochemistry in 295 cases with various degrees of cervical epithelial lesions, including 78 normal cervical epithelia, 31 mild dysplasia (CIN I), 77 moderate-severe dysplasia (CIN II–III), and 109 squamous cervical carcinomas (SCCs), and their association with various clinical pathologic prognostic variables were analyzed in 73 early-stage SCC patients who underwent surgery. Hes1 and Hes5 expression were found to be significantly higher in SCC compared with CIN as well as higher in CIN than normal cervical epithelia, and positively correlated with various prognostic factors in early-stage cervical carcinoma. Our findings suggest that Hes1 and Hes5 may be involved in carcinogenesis of the cervix and progression of cervical carcinoma. Hes1 and Hes5 overexpression are probably variables to predict poor prognosis of the patients with early-stage cervical carcinoma

scholarly journals Survival Rate Analysis of Early Stage Cervical Cancer Patients after Radical Hysterectomy in Ulin Banjarmasin General Hospital, Indonesia

2021 ◽  
Vol 17 (1) ◽  
pp. 39
Author(s):  
Setyo Teguh ◽  
Hariadi Hariadi ◽  
Ferry Armanza ◽  
Hermin Sabaruddin
Keyword(s):  
Cervical Cancer ◽  
Survival Rate ◽  
Cervical Carcinoma ◽  
Radical Hysterectomy ◽  
Early Stage ◽  
P Value ◽  
Chi Square ◽  
Average Life Span ◽  
Stage Ib ◽  
Rate Analysis

Abstract: Cervical cancer is a gynecologic disease that has a high level of malignancy and is a major cause of death from cancer in women. To be used as educational material for patients with cervical carcinoma when if there is known outcome of radical hysterectomy in patients with IB-IIA cervical carcinoma, it can be used as a basic data to know the success rate of radical hysterectomy.The sample was collected by consecutive sampling and we found a total of 55 IB-IIA cervical carcinoma patients who underwent a radical hysterectomy. The samples that met the inclusion criteria are 30 people. Data analysis using Chi-square/Fisher method (significant p-value <0.05).In this study, 16.7% of patients with cervical carcinoma from IB to IIA died in 3 years after radical hysterectomy was performed. The average age of patients with stage IB to IIA cervical carcinoma was 48.03 ± 12.21 years with ages ranging from 23 to 78 years. Stage IIA is 16 times more significantly at risk for mortality in cervical carcinoma patients than stage IB. The 3-year survival rate for patients with stage IB to IIA cervical carcinoma after radical hysterectomy was 83.3% with an average life span of 32.8 months. Patients with stage IB to IIA cervical carcinoma after radical hysterectomy have an average disease-free interval (DFI) of 33.0 ± 5.74 months. Keywords: Cervical Cancer, Radical Hysterectomy, Survival Rate

scholarly journals Impact of examined lymph node count on long-term survival of T1-2N0M0 double primary NSCLC patients after surgery: a SEER study

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e8692 ◽  
Author(s):  
Kan Jiang ◽  
Xiaohui Zhi ◽  
Yue Shen ◽  
Yuanyuan Ma ◽  
Xinyu Su ◽  
...  
Keyword(s):  
Cox Regression ◽  
Early Stage ◽  
Cancer Specific Survival ◽  
Term Survival ◽  
Cutoff Value ◽  
Long Term Survival ◽  
Lymph Node Count ◽  
Primary Nsclc ◽  
Nsclc Patients

Purpose The relationship between examined lymph nodes (ELN) and survival has been confirmed in several single early-stage malignancies. We studied the association between the ELN count and the long-term survival of T1-2N0M0 double primary non-small cell lung cancer (DP-NSCLC) patients after surgery, based on the Surveillance, Epidemiology and End Results (SEER) database. Methods A total of 948 patients were identified and their independent prognostic factors were analyzed. These factors included the ELN count, which related to overall survival (OS) and the cancer-specific survival (CSS) of synchronous (n = 426) and metachronous (n = 522) T1-2N0M0 DP-NSCLC patients after surgery. Results X-tile analysis indicated that the cutoff value for the sum of ELNs was 22 for both OS and CSS in the synchronous DP-NSCLC group. Patients with a sum of ELNs >22 were statistically more likely to survive than those with ≤22 ELNs. X-tile analysis revealed that the ELN count of the second lesion was related to both OS and CSS in the metachronous DP-NSCLC group. The optimal cutoff value was nine. These results were confirmed using univariate and multivariate Cox regression analyses. Conclusion Our findings indicate that ELN count was highly correlated with the long-term survival of T1-2N0M0 double primary NSCLC patients after surgery.

scholarly journals The Modern Chemical Theory of Ovarian Cancer Origin

2019 ◽  
Vol 70 (3) ◽  
pp. 1026-1029
Author(s):  
Mihaela Alina Calin ◽  
Elena Mihalceanu ◽  
Mihaela Debita ◽  
Gheorghe Raftu ◽  
Gabriel Costachescu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Survival Rate ◽  
Early Stage ◽  
Point Of View ◽  
Term Survival ◽  
Chemical Theory ◽  
Modern Chemical ◽  
Complex Development ◽  
Therapeutic Attitude

Because of its histological and embryological complex development, the ovary can be the source of a large variety of tumors, ovarian cancer being the fifth female neoplasia as a frequency. A major clinical significance is that the ovarian tumor is asymptomatic for a long period of time.Ovarian proliferative pathology raises a number of important issues from both theoretical and practical point of view. The change in the therapeutic attitude, especially in the areas of surgery and chemotherapy, has led in the last decades to an improvement in the survival rate. Our retrospective study included the analysis of 64 patients with ovarian cancer. Ovarian neoplasms should have a multidisciplinary approache with individualized treatment for each patient. The long-term survival remains, however, the detection of the tumor at an early stage, the undetectment in the initial stages leading to a survival rate of 5 years less than 20%.

Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26–30

2021 ◽  
Author(s):  
Shi-Ping Yang ◽  
Jia Yao ◽  
Ping Zhou ◽  
Chen-Lu Lian ◽  
Jun Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Recurrence Score ◽  
Tumor Grade ◽  
Early Stage Breast Cancer ◽  
Sensitivity Analyses ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival ◽  
Chemotherapy Patients

Aim: To investigate the benefit of chemotherapy among early-stage breast cancer patients with 21-gene recurrence scores of 26–30. Methods: We identified 3754 patients in the Surveillance, Epidemiology, and End Results database. Results: 57.6% of the patients received adjuvant chemotherapy. Patients with higher tumor grade, larger tumors and younger age were more likely to receive chemotherapy. The receipt of chemotherapy was independently associated with better breast cancer-specific survival than in patients without chemotherapy before (p = 0.016) and after (p = 0.043) propensity score matching. The sensitivity analyses showed that survival gain was pronounced in patients with poorly differentiated or undifferentiated disease. Conclusions: Adjuvant chemotherapy improves the outcome for early-stage breast cancer with 21-gene recurrence score of 26–30, especially for patients with high-grade tumors.

Role of Human Papillomavirus Genotype in Prognosis of Early-Stage Cervical Cancer Undergoing Primary Surgery

2007 ◽  
Vol 25 (24) ◽  
pp. 3628-3634 ◽  
Author(s):  
Chyong-Huey Lai ◽  
Chee-Jen Chang ◽  
Huei-Jean Huang ◽  
Swei Hsueh ◽  
Angel Chao ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Carcinoma ◽  
Dna Sequences ◽  
Early Stage ◽  
Prognostic Significance ◽  
Figo Stage ◽  
Stromal Invasion ◽  
Hpv Dna ◽  
Primary Surgery ◽  
Hpv 18

Purpose Our aim was to evaluate the prognostic significance of human papillomavirus (HPV) genotype in early-stage cervical carcinoma primarily treated with surgery in a large tertiary referral medical center. Patients and Methods Consecutive patients who underwent primary surgery for invasive cervical carcinoma of International Federation of Gynecology and Obstetrics (FIGO) stage I to IIA between 1993 and 2000 were retrospectively reviewed. Polymerase chain reaction (PCR) using a general primer set followed by reverse-blot detection of 38 types of HPV DNA in a single reaction was performed for genotyping. E6 type-specific PCR was performed to validate multiple types. Results A total of 1,067 eligible patients were analyzed. HPV DNA sequences were detected in 95.1% of the specimens, among which 9.6% contained multiple types. HPV 16 was detected in 63.8% of the samples, and HPV 18 was detected in 16.5% of the samples. The median follow-up time of surviving patients was 77 months. By multivariate analysis, FIGO stage, lymph node metastasis, depth of cervical stromal invasion, grade of differentiation, and HPV 18 positivity were significantly related to cancer relapse. FIGO stage II, deep stromal invasion, parametrial extension, HPV 18 positivity, and age older than 45 years were significant predictors for death. Using the seven selected variables from either recurrence-free or overall survival analysis, death-predicting (P < .0001) and relapse-predicting (P < .0001) models classifying three risk groups (low, intermediate, and high risk) were constructed and endorsed by internal validation. Conclusion The independent prognostic value of HPV genotype is confirmed in this study. The prognostic models could be useful in counseling patients and stratifying patients in future clinical trials.

Sign in / Sign up

Export Citation Format

Share Document